Oncolytics Biotech Inc. leads the precision medicine market with $69.16 billion growth.

The oncology landscape is expected to experience significant growth, driven by the integration of genotype-directed treatment pathways into standard medical practice. The precision medicine market is projected to expand from $138.67 billion in 2026 to over $537.17 billion by 2035. Oncolytics Biotech Inc. (NASDAQ: ONCY), CG Oncology (NASDAQ: CGON), Zentalis Pharmaceuticals (NASDAQ: ZNTL), ArriVent BioPharma (NASDAQ: AVBP), and PDS Biotechnology (NASDAQ: PDSB) are strategic players in this high-velocity regulatory phase, fueled by the growth of the orphan drug market from $216.66 billion in 2025 to $687.47 billion by 2032.